RabMAb

Anti-Cdk4 antibody [EPR4513] (ab108357)

Overview

  • Product nameAnti-Cdk4 antibody [EPR4513]
    See all Cdk4 primary antibodies
  • Description
    Rabbit monoclonal [EPR4513] to Cdk4
  • Tested applicationsWB, IHC-P, ICC, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Cdk4 (C terminal).

  • Positive control
    • Hela, MCF7, K562, and Ramos cell lysates. Human urothelial carcinoma tissue
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A 40 µl trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Alternative versions available:

    Anti-Cdk4 antibody (Alexa Fluor® 488) [EPR4513] (ab193966)

    Anti-Cdk4 antibody (Alexa Fluor® 647) - Loading Control [EPR4513] (ab193967)
    Anti-Cdk4 antibody (HRP) - Loading Control [EPR4513] (ab193968)

Properties

Applications

Our Abpromise guarantee covers the use of ab108357 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 34 kDa (predicted molecular weight: 34 kDa).
IHC-P 1/100 - 1/250. Antigen retrieval is recommend.
ICC 1/100 - 1/250.
Flow Cyt 1/10 - 1/100. Ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
  • Application notesIs unsuitable for IP.
  • Target

    • FunctionSer/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
    • Involvement in diseaseDefects in CDK4 are a cause of susceptibility to cutaneous malignant melanoma type 3 (CMM3) [MIM:609048]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
    • Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Phosphorylation at Thr-172 is required for enzymatic activity. Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo, appears to be phosphorylated by a proline-directed kinase. In the cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4 enzyme activity, is dependent on the tyrosine phosphorylation state of CDKN1B. Thus, in proliferating cells, CDK4 within the complex is phosphorylated on Thr-172 in the T-loop. In resting cells, phosphorylation on Thr-172 is prevented by the non-tyrosine-phosphorylated form of CDKN1B.
    • Cellular localizationCytoplasm. Nucleus. Membrane. Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • Cdk 4 antibody
      • cdk4 antibody
      • CDK4 protein antibody
      • CDK4_HUMAN antibody
      • Cell division kinase 4 antibody
      • Cell division protein kinase 4 antibody
      • CMM 3 antibody
      • CMM3 antibody
      • Crk3 antibody
      • Cyclin dependent kinase 4 antibody
      • Cyclin-dependent kinase 4 antibody
      • Melanoma cutaneous malignant 3 antibody
      • MGC14458 antibody
      • p34 cdk4 antibody
      • PSK J3 antibody
      • PSK-J3 antibody
      see all

    Anti-Cdk4 antibody [EPR4513] images

    • All lanes : Anti-Cdk4 antibody [EPR4513] (ab108357) at 1/1000 dilution

      Lane 1 : Human osteosarcoma whole cell lysate - control, non-targeting siRNA
      Lane 2 : Human osteosarcoma whole cell lysate - siRNA for CDK4

      Lysates/proteins at 20 µg per lane.

      Secondary
      HRP-conjugated goat anti-rabbit IgG polyclonal at 1/2000 dilution
      developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 34 kDa
      Observed band size : 34 kDa


      Exposure time : 5 seconds

      This image is courtesy of an Abreview submitted by Sonia Rocha

      See Abreview

    • All lanes : Anti-Cdk4 antibody [EPR4513] (ab108357) at 1/1000 dilution

      Lane 1 : Hela cell lysate
      Lane 2 : MCF7 cell lysate
      Lane 3 : K562 cell lysate
      Lane 4 : Ramos cell lysate

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 34 kDa
      Observed band size : 34 kDa
    • ab108357, at a 1/100 dilution, staining Cdk4 in paraffin embedded Human urothelial carcinoma tissue by Immunohistochemistry.
    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

    References for Anti-Cdk4 antibody [EPR4513] (ab108357)

    ab108357 has not yet been referenced specifically in any publications.

    Product Wall

    Application Western blot
    Loading amount 20 µg
    Gel Running Conditions Reduced Denaturing (10%)
    Sample Human Cell lysate - whole cell (osteosarcoma cells)
    Specification osteosarcoma cells
    Treatment lane 1 control, lane 2 siRNA for CDK4, 48h
    Blocking step Milk as blocking agent for 10 minute(s) · Concentration: 10% · Temperature: 21°C
    Username

    Dr. Sonia Rocha

    Verified customer

    Submitted Sep 26 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"